enGenes presents high-titer continuous plasmid DNA production solution to ISCT Dublin

Vienna, Austria: – End-to-end bioprocessing specialist CDMO enGenes Biotech will bring details of its groundbreaking iCAP plasmid DNA continuous production platform to the upcoming annual meeting of the International Society for Cell & Gene Therapy (ISCT) in Dublin.

enGenes CEO Dr Jürgen Mairhofer will lead the company’s presence at the conference, which has become recognized as one of the world’s leading events in the field of Cell and Gene Therapy (CGT) Translation, attracting more than 3,000 delegates from at least 60 countries.

iCAP continuous pDNA project

Dr. Mairhofer will provide an oral ‘elevator pitch’ summary of the enGenes poster submitted to the ISCT conference “iCAP – An Integrated, Continuous and Automated Platform for High-Titer Plasmid DNA Production.”

This will summarise enGenes Biotech’s progress in pioneering an advanced, high-yield, and low-consumption end-to-end continuous pDNA manufacturing platform that leverages its proprietary enGenes-eXcess technology. This optimizes upstream and downstream processes to enable significant yield improvements for precise and reproducible production of high-quality plasmid DNA in a cost-effective manner.

To read the whole article, click here https://www.pharmaceutical-networking.com/engenes-presents-high-titer-continuous-plasmid-dna-production-solution-to-isct-dublin/